Phreesia (NYSE:PHR) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Phreesia has received a sell (D-) rating from Weiss Ratings, despite recent price target increases from other analysts, highlighting mixed sentiment on the stock.
• The company's quarterly earnings exceeded expectations with reported EPS of $0.01, contrasting the consensus estimate of ($0.07), indicating growth potential.
• Phreesia's stocks opened at $23.25 with a market cap of $1.39 billion and a price-to-earnings ratio of -55.36, reflecting financial challenges despite revenue growth.

Phreesia (NYSE:PHR - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts have also issued reports about the stock. Needham & Company LLC raised their target price on shares of Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Citigroup reiterated an "outperform" rating on shares of Phreesia in a research note on Monday, September 8th. KeyCorp lowered their target price on shares of Phreesia from $35.00 to $32.00 and set an "overweight" rating on the stock in a research note on Wednesday. Piper Sandler raised their target price on shares of Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a research note on Friday, September 5th. Finally, JMP Securities raised their target price on shares of Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.85.

Phreesia Stock Performance

Shares of PHR opened at $23.25 on Wednesday. The company's fifty day moving average is $26.69 and its 200-day moving average is $26.19. Phreesia has a 12 month low of $17.07 and a 12 month high of $32.76. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -55.36 and a beta of 0.68. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same period in the prior year, the firm earned ($0.03) EPS. Phreesia's quarterly revenue was up 14.9% compared to the same quarter last year. Phreesia has set its FY 2026 guidance at EPS. Equities analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Transactions at Phreesia

In other Phreesia news, insider Evan Roberts sold 3,761 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $87,556.08. Following the completion of the sale, the insider directly owned 726,837 shares of the company's stock, valued at $16,920,765.36. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Linetsky sold 1,064 shares of the firm's stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $23.50, for a total transaction of $25,004.00. Following the transaction, the insider directly owned 173,888 shares of the company's stock, valued at $4,086,368. The trade was a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,241 shares of company stock worth $2,766,062. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently made changes to their positions in PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after acquiring an additional 1,377,904 shares during the period. Loomis Sayles & Co. L P bought a new position in shares of Phreesia during the 2nd quarter worth about $34,162,000. American Century Companies Inc. lifted its holdings in shares of Phreesia by 3,741.9% during the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock worth $25,137,000 after acquiring an additional 957,842 shares during the period. Nuveen LLC bought a new position in shares of Phreesia during the 1st quarter worth about $14,206,000. Finally, Champlain Investment Partners LLC lifted its holdings in Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock valued at $75,312,000 after purchasing an additional 490,340 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.